(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -31.13% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Aclaris Therapeutics's revenue in 2025 is $17,778,000.On average, 6 Wall Street analysts forecast ACRS's revenue for 2025 to be $670,369,151, with the lowest ACRS revenue forecast at $563,062,443, and the highest ACRS revenue forecast at $779,624,921. On average, 6 Wall Street analysts forecast ACRS's revenue for 2026 to be $619,152,125, with the lowest ACRS revenue forecast at $97,453,115, and the highest ACRS revenue forecast at $1,082,812,390.
In 2027, ACRS is forecast to generate $647,196,966 in revenue, with the lowest revenue forecast at $433,124,956 and the highest revenue forecast at $769,879,609.